| ¿µ¹® | immune system | ÇÑ±Û | ¸é¿ªÃ¼°è |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷¼ººÐ ¹× ºÐÀÚ¼ººÐÀÇ º¹ÇÕü°è·Î¼, ÀÌÀÇ ÀÏÂ÷±â´ÉÀº ÀÚ±â(self)¸¦ ºñÀÚ±â(not self)·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ»ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇÏ´Â °ÍÀÌ´Ù. ÀÏÂ÷ÀûÀÎ ¼¼Æ÷¼ººÐÀº ¸²ÇÁ±¸¿Í Å«Æ÷½Ä¼¼Æ÷À̸ç ÀÏÂ÷ÀûÀÎ ºÐÀÚ¼ººÐÀº Ç×ü¿Í ¸²Æ÷Ä«ÀÎÀÌ´Ù. |
||
| ¿µ¹® | urinary system | ÇÑ±Û | ºñ´¢±â°èÅë |
|---|---|---|---|
| ¼³¸í | ºñ´¢±â°èÅëÀ̶óÇϸé ÄáÆÏÀ¸·ÎºÎÅÍ ½ÃÀÛÇØ¼ ¿ä°ü, ¹æ±¤, ¿äµµ¿¡ À̸£´Â ÀÏ·ÃÀÇ ¿ÀÁÜ»ý¼º ¹× ÀúÀå, ¹è¼³±â°üÀ» ÀÏÄ´´Ù. ÄáÆÏÀº ±æÀÌ ¾à 2.5cm, Æø ¾à 5.1cm, µÎ²² ¾à 2.5cm, ¹«°Ô ¾à 120~160gmÀ¸·Î¼, ³»Ãø¿¡ ÄáÆÏ¹®ÀÌ ÀÖ¾î Ç÷°ü, ½Å°æ, ¿ä°üÀÌ ÃâÀÔÇϰí ÀÖ´Ù. ÄáÆÏÀº ¼ÓÁú°ú °ÑÁú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¼öÁúÀº 10~15°³ÀÇ Ãßü(¿ÀÁÜÀ» ¸ðÀ¸´Â ¿ªÇÒ)¸¦ Çü¼ºÇÏ°í °ÑÁúÀº ¾à 100¸¸°³ÀÇ ÄáÆÏ´ÜÀ§À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¿ä¼¼°üÀº Å丮ÂÊ´¢¼¼°ü, Çî·¹°í¸®, ¸ÕÂÊ´¢¼¼°ü, ÁýÇÕ°üÀ¸·Î Çü¼ºµÇ¾î ÀÖÀ¸¸ç, Ãßü¿Í ¼úÀÜ, ±ò¶§±â¸¦ °ÅÃÄ ¿ä°üÀ¸·Î ¿¬°áµÈ´Ù. ÄáÆÏÀº Ç÷¾×À» ¿©°úÇÏ¿© ½Åü ½ÅÁø´ë»çÀÇ ÃÖÁ¾»ê¹°À» ¿ÀÁÜÀÇ ÇüÅ·Π¹è¼³Çϸç, ¼¼Æ÷¿Ü¾×(extracellular fluid)ÀÇ ÀüÇØÁú³óµµ¸¦ Á¶ÀýÇÑ´Ù. ÄáÆÏ¿¡¼ Çü¼ºµÈ ¿ÀÁÜ´Â ¿ä°üÀ» °ÅÃÄ ¹æ±¤¿¡¼ ÀúÀåµÇ°í ÀÖ´Ù°¡ Àû´çÇÑ ½Ã±â°¡ µÇ¸é ¿äµµ¸¦ ÅëÇØ ¿Ü°è·Î ¹èÃâµÈ´Ù. |
||
| ¿µ¹® | reproductive system | ÇÑ±Û | »ý½Ä±â°èÅë |
|---|---|---|---|
| ¼³¸í | 1.³²¼º»ý½Ä°èÅë: ³²¼º»ý½Ä±â´Â Á¤ÀÚ(sperm)¸¦ »ý¼ºÇÏ´Â °íȯ°ú Á¤ÀÚÀÇ ¼º¼÷, ¿î¹Ý, ±×¸®°í »çÁ¤¿¡ °ü¿©ÇÏ´Â ºÎ°íȯ, Á¤°ü, À½°æ(penis) µîÀ¸·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç, ºÎ¼Ó±â°üÀ¸·Î ¿ÜºÐºñ»ùÀÎ Á¤³¶(seminal vesicle), Àü¸³»ù(prostate), ¿äµµ¸Á¹°»ù(bulbourethral gland, Cowper¡¯s gland) µîÀ» °®Ãß°í ÀÖ´Ù. °íȯÀº Á¤ÀÚ¸¦ »ý»êÇÏ´Â »ý½Ä»ùÀÎ µ¿½Ã¿¡ ³²¼ºÈ£¸£¸ó(testosterone)À» ºÐºñÇÏ´Â ³»ºÐºñ»ùÀÌ´Ù. °íȯ¿¡¼ ºÐºñµÇ´Â ³²¼ºÈ£¸£¸óÀº Á¤ÀÚ»ý¼º°ú »ý½Ä±âÀÇ ¹ß´Þ ¹× À¯Áö¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇϹǷΠ³²¼º»ý½Ä±â´ÉÀÇ ¿øÃµÀº °íȯ¿¡ ÀÖ´Ù°í º¼ ¼ö ÀÖ´Ù. 2.¿©¼º»ý½Ä°èÅë: ¿©¼º»ý½Ä±â´Â ³ÀÚ¸¦ »ý¼ºÇÏ´Â ³¼Ò¿Í ³ÀÚ¸¦ ÀÚ±ÃÀ¸·Î ¿î¹ÝÇÏ´Â ³°ü, ±×¸®°í Àڱðú Áú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¿ÜºÐºñ¼±ÀÎ ¹Ù¸£Å縰»ù¸¦ °®Ãß°í ÀÖ´Ù. ³¼Ò´Â ³ÀÚ¸¦ »ý¼ºÇÏ´Â »ý½Ä»ùÀÎ µ¿½Ã¿¡ ¿©¼ºÈ£¸£¸óÀ» ºÐºñÄÉÇÏ´Â ³»ºÐºñ»ùÀÌ´Ù. ¿ù°æÁÖ±â Àü¹ÝºÎ¿¡ ³ÀÚ¸¦ »ý¼º½Ã۱âÀ§ÇØ ¼º¼÷µÇ°í ÀÖ´Â ³Æ÷¿¡¼ ºÐºñµÇ´Â ¿¡½ºÆ®·Î°ÕÀº ¿©¼º 2Â÷ ¼ºÂ¡ÀÇ ¹ß´ÞÀ» °üÀåÇÒ »Ó ¾Æ´Ï¶ó Àڱ󻸷À» ÀåÂ÷ ¼öÁ¤µÉ ¼öÁ¤¶õÀÌ Âø»óÇϱ⿡ ¾Ë¸ÂÀº »óÅ·Π¸¸µé¾îÁØ´Ù. ³ÀÚ°¡ ºÐºñµÇ°í ³²Àº Ȳü¿¡¼ ºÐºñµÇ´Â Ǫ·Î°Ô½ºÅ×·ÐÀº Àڱ󻸷À» º×µµ·Ï ÇÏ¸é ºÐºñ¾×À» Áõ°¡½Ã۸ç ÀڱñÙÀÇ ¼öÃàÀ» ¹æÇØÇÏ¿© ÀӽŽà ÀÓ½ÅÀ» Áö¼Ó½ÃŰ´Â ¿ªÇÒÀ» ÇÑ´Ù. |
||
| ¿µ¹® | digestive system | ÇÑ±Û | ¼Òȱâ°èÅë |
|---|---|---|---|
| ¼³¸í | ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼ ºÎ¸£´Â ¸». |
||
| ¿µ¹® | nervous system | ÇÑ±Û | ½Å°æ°è |
|---|---|---|---|
| ¼³¸í | ¿©·¯ ±â°üµéÀÇ ¼·Î°£ »óÈ£¿¬°áü°è°¡ ¹Ù·Î ½Å°æ°èÀÌ´Ù. ¿©±â¿¡´Â ÁßÃ߽Űæ°è(central nerve system: CNS)¿Í ¸»ÃʽŰæ°è(peripheral nerve system: PNS)°¡ Àִµ¥, ÁßÃ߽Űæ°è¶õ ³ú¿Í ô¼ö¸¦ ¸»ÇÑ´Ù. ±×¸®°í ¸»ÃʽŰæ°è¿¡´Â 12½ÖÀÇ ³ú½Å°æ(cranial nerve: ³ú¿¡¼ ±â½ÃÇÏ¿© ÁÖ·Î ¾ó±¼ºÎÀ§¿Í ¸ñ ºÎÀ§¿¡ ºÐÆ÷ÇÑ´Ù)°ú 31½ÖÀÇ Ã´¼ö½Å°æ(spinal nerve:spinal cord¿¡¼ °¢±â ¾çÂÊÀ¸·Î ½ÖÀ» ÀÌ·ç¾î ³ª¿À´Âµ¥ ÁÖ·Î ¸ñÀÌÇϺÎÀ§ÀÇ ½Åü °¢ºÎºÐÀ¸·Î ºÐÆ÷ÇÏ°Ô µÈ´Ù)À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¶ÇÇÑ ¸»ÃʽŰæ°è´Â 3°¡ÁöÀÇ ½Å°æÁ¶Á÷µé·Î ±¸¼ºµÇ¾î Àִµ¥ ¾Õ¿¡¼ ¸»ÇÑ ³ú½Å°æ°ú ô¼ö½Å°æ¿Ü¿¡ ÀÚÀ²½Å°æ°è°¡ ¿©±â¿¡ ÇØ´çµÈ´Ù. ÀÚÀ²½Å°æ°è´Â ´Ù½Ã ±³°¨½Å°æ°ú ºÎ±³°¨½Å°æÀ¸·Î ³ª´µ¾îÁ® ¼·Î°£ÀÇ ¿Ã¹Ù¸¥ »óÈ£ÀÛ¿ëÀ¸·Î »ýü ¿©·¯ °¡Áö ÀÛ¿ëÀ» ¼öÇàÇÑ´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| GA | Gamblers Anonymous; gastric analysis; gastric antrum; general anesthesia; general angiography; gener... |
| HGO | hepatic glucose output; human glucose output |
| BLS | bare lymphocyte syndrome; basic life support; blind loop syndrome; blood and lymphatic system; blood... |
| MN | a blood group in the MNSs blood group system; malignant nephrosclerosis; Master of Nursing; meganewt... |
| glucose-3-phosphatase | <enzyme> From rat liver; has glucose-3-phosphate hydrolytic activity Registry number: EC 3.1.3.- (26 Jun 1999) |
|---|---|
| glucose-6-dehydrogenase deficiency | <biochemistry> An inherited condition that results in a deficiency in glucose-6-phosphate dehydrogenase. Particular drugs (sulphonamides) can exacerbate this problem. The result is haemolytic anaemia. (27 Sep 1997) |
| glucose-6-phosphatase | <enzyme> An enzyme that catalyses the conversion of d-glucose-6-phosphate and water to d-glucose and orthophosphate. This enzyme is deficient in glycogen storage disease Ia. Chemical name: D-Glucose-6-phosphate phosphohydrolase Registry number: EC 3.1.3.9 (12 Dec 1998) |
| glucose-6-phosphatase hepatorenal glycogenosis | Glycogenosis due to glucose-6-phosphatase deficiency, resulting in accumulation of excessive amounts of glycogen of normal chemical structure, particularly in liver and kidney. Synonym: Gierke's disease, glucose-6-phosphatase hepatorenal glycogenosis, von Gierke's disease. (05 Mar 2000) |
| glucose-6-phosphate | <biochemistry> Glucose 6-phosphate is a phosphomonoester of glucose that is formed by transfer of phosphate from ATP, catalysed by the enzyme hexokinase. It is an intermediate both of the glycolytic pathway (next converted to fructose 6 phosphate) and of the NADPH generating pentose phosphate pathway, formed from glucose via hexokinase. However it is not strictly a glycolytic intermediate and it is readily converted to glycogen or oxidized to NADPH. (10 Oct 1997) |
| glucose-6-phosphate dehydrogenase | <enzyme> An NADP+ enzyme that catalyses the dehydrogenation (oxidation) of d-glucose-6-phosphate to 6-phospho-d-glucono-d-lactone, this reaction initiating the Dickens shunt. Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people. The gene for this enzyme is on the X chromosome. Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans. Synonym: Robison ester dehydrogenase, Zwischenferment. Acronym: G6PD (12 Sep 2002) |
| glucose-6-phosphate dehydrogenase deficiency | A deficiency of glucose-6-phosphate dehydrogenase, an enzyme important for maintaining cellular concentrations of reduced nucleotides. Deficiency of this enzyme is the commonest disease-causing enzyme defect in humans affecting an estimated 400 million people. The gene for this enzyme is on the X chromosome and there are various polymorphic forms. Males with the enzyme deficiency develop haemolytic anaemia when red blood cells are exposed to oxidant drugs such as the antimalarial primaquine, the sulfonamide antibiotics or sulfones, naphthalene moth balls, or fava beans. It can also cause anaemia of the newborn, and chronic nonspherocytic haemolytic anaemia. Inheritance: X-linked. (12 Sep 2002) |
| glucose-6-phosphate isomerase | <enzyme> An enzyme that catalyses the reversible interconversion of glucose-6-phosphate and fructose-6-phosphate, and is a part of the glycolytic and gluconeogenic pathways. Deficiency of the enzyme, an autosomal recessive trait, results in liver glycogenesis and haemolytic anaemia. Chemical name: D-Glucose-6-phosphate ketol-isomerase Registry number: EC 5.3.1.9 (12 Dec 1998) |
| glucose-6-phosphate translocase | <enzyme> A component of EC 3.1.3.9 which transports glucose phosphate into endoplasmic reticulum Registry number: EC 2.7.- Synonym: t1 transport protein (26 Jun 1999) |
| glucose clamp technique | <technique> Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration. (12 Dec 1998) |
| glucose dehydrogenase | <enzyme> Converts beta-d-glucose to d-glucono-d-lactone, transferring hydrogen to NAD+ or NADP+. Compare: glucose oxidase. (05 Mar 2000) |
| glucose dehydrogenases | <enzyme> D-glucose:1-oxidoreductases. Catalyses the oxidation of d-glucose to d-glucono-gamma-lactone and reduced acceptor. Any acceptor except molecular oxygen is permitted. Registry number: EC 1.1.1. (12 Dec 1998) |
| glucose effect | <biochemistry> The ability of the sugar glucose to block sugar metabolism by keeping the genes which make the enzymes involved in the early steps of sugar metabolism from making those enzymes. (09 Oct 1997) |
| glucose-fructose oxidoreductase | <enzyme> Isolated from zymomonas mobilis; catalyses the formation of sorbitol and glucono-delta-lactone from glucose and fructose; enzyme contains tightly bound nadp+ Registry number: EC 1.1.99.- (26 Jun 1999) |
| glucose intolerance | A pathological state in which the fasting plasma glucose level is less than 140 mg per deciliter and the 30-, 60-, or 90-minute plasma glucose concentration following a glucose tolerance test exceeds 200 mg per deciliter. This condition is seen frequently in diabetes mellitus but also occurs with other diseases. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|